Large gap with delayed quotes
|
Last quote
09/04/2025
-
02:00:00
|
Bid
09/03/2025 -
21:59:59
|
Bid Volume |
Ask
09/03/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
49.99
+0.37
(
+0.75% )
|
50.00
|
900 |
50.01
|
200 |
Analysis date: 02.09.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 15.08.2025.
Interest
Weak
Weak
Two stars since 02.09.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 29.04.2025 at a price of 41.29.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 15.08.2025.
4wk Rel Perf
32.40%
32.40%
The four-week dividend-adjusted overperformance versus SP500 is 32.40%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 02.05.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.41%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.91%.
Mkt Cap in $bn
5.93
5.93
With a market capitalization between $2 & $8bn, CYTOKINETICS is considered a mid-cap stock.
G/PE Ratio
-0.16
-0.16
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-13.02
-13.02
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-2.04%
-2.04%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
17
17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
57
57
For 1% of index variation, the stock varies on average by 0.57%.
Correlation
0.17
0.17
Stock movements are totally independent of index variations.
Value at Risk
38.46
38.46
The value at risk is estimated at USD 38.46. The risk is therefore 77.52%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
31.08.2005
31.08.2005